07:00 , Oct 24, 2011 |  BC Week In Review  |  Company News

LCT, Otsuka Pharmaceutical deal

Living Cell and Otsuka will establish a 50/50 JV, to be named Diatranz Otsuka Ltd., to develop and commercialize Living Cell's DiabeCell worldwide, except for China. Otsuka will contribute A$25 million ($25.9 million) to the...
07:00 , Apr 18, 2011 |  BC Week In Review  |  Company News

LCT, Otsuka Pharmaceutical deal

Living Cell said it has begun negotiations to grant Otsuka rights to develop and commercialize Living Cell's DiabeCell in Japan and other Asian countries, excluding China. DiabeCell, which comprises encapsulated porcine pancreatic islet cells, is...
07:00 , Mar 21, 2011 |  BC Week In Review  |  Company News

Jiangsu Aosaikang Pharmaceutical Co. Ltd., LCT deal

Jiangsu and Living Cell are in negotiations to enter a research collaboration which proposes Jiangsu receive a right to first refusal to negotiate exclusive commercialization rights for Living Cell's DiabeCell in China. DiabeCell, which comprises...
08:00 , Nov 15, 2010 |  BC Week In Review  |  Clinical News

DiabeCell: Interim Phase II data

Interim data from 4 patients in an ongoing, dose-ranging, New Zealand Phase II trial showed that 1 DiabeCell implant of 10,000 islet equivalents/kg reduced the severity of hypoglycemic events by 64% at week 24. DiabeCell...
07:00 , Aug 9, 2010 |  BC Week In Review  |  Clinical News

DiabeCell: Phase II expanded

Living Cell received approval to expand enrollment to 12 patients from 8 in an ongoing dose-ranging, New Zealand Phase II trial evaluating Diabecell implants. Living Cell Technologies Ltd. (ASX:LCT; OTCQX:LVCLY), Sydney, Australia   Product: DiabeCell...
07:00 , May 3, 2010 |  BioCentury  |  Finance

Regulatory Milestones

Regulatory milestones Avanir Pharmaceuticals Inc. (NASDAQ:AVNR) gained $0.12 to $3.22 last week after the company submitted a complete response to a 2006 FDA approvable letter for Zenvia dextromethorphan/quinidine to treat pseudobulbar affect (PBA). Pharmaxis Ltd....
07:00 , Apr 12, 2010 |  BC Week In Review  |  Clinical News

DiabeCell: Additional Phase I/IIa data

Additional data from a Russian Phase I/IIa trial in 8 patients showed that DiabeCell implant reduced HbA1c in 6 patients by 0.2-2.8% and reduced daily insulin by 13-100% at 6 months. In 5 patients receiving...
07:00 , Apr 5, 2010 |  BC Week In Review  |  Clinical News

DiabeCell: Phase I/IIa ongoing

Based on a review of data from the first 4 patients, a DSMB recommended continuation of a New Zealand Phase I/IIa trial of DiabeCell at a higher dose level. The next 4 patients will receive...
08:00 , Dec 14, 2009 |  BC Week In Review  |  Clinical News

DiabeCell: Interim Phase I/IIa data

Interim data from an open-label, dose-escalation, New Zealand Phase I/IIa trial showed that the daily insulin dose for 1 patient receiving the DiabeCell implant had started to drop by 30%, while maintaining his usual blood...
07:00 , Jul 27, 2009 |  BC Week In Review  |  Clinical News

DiabeCell: Phase I/IIa started

Living Cell Technologies began an open-label, dose-escalation, New Zealand Phase I/IIa trial to evaluate DiabeCell implant in 8 patients with poorly controlled diabetes. Living Cell Technologies Ltd. (ASX:LCT; OTCQX:LVCLY), Sydney, Australia   Product: DiabeCell  ...